共 56 条
[1]
Bonaca MP(2019)Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology Circulation 140 80-91
[2]
Olenchock BA(2021)Immune checkpoint inhibitor-associated myasthenia gravis, myositis and myocarditis overlap syndrome Am J Emerg Med 46 51-55
[3]
Salem JE(2020)Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series Cardiooncology. 6 21-47
[4]
Wiviott SD(2021)The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity JACC CardioOnc 3 35-1764
[5]
Ederhy S(2018)Myocarditis in patients treated with immune checkpoint inhibitors J Am Coll Cardiol 71 1755-e458
[6]
Cohen A(2018)Immune checkpoint inhibitors and cardiovascular toxicity Lancet Oncol 19 e447-1767
[7]
Lipe DN(2018)Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-immuno-oncology J Am Coll Cardiol 71 1765-947
[8]
Galvis-Carvajal E(2019)Takotsubo syndrome in patinets with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication Eur J Heart Fail 21 945-481
[9]
Rajha E(2020)Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of life-threatening adverse event Can J Cardiol 36 476-456
[10]
Wechsler AH(2020)Drug induced acute coronary syndrome: a new cardiovascular concern with immune checkpoint inhibitors and the need for a prospective registry Can J Cardiol 36 455-undefined